Genmab Outlicenses Zanolimumab to TenX Biopharma
Under the terms of the agreement, Genmab receives a payment of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX Biopharma will be responsible for all future costs of developing, manufacturing and commercializing zanolimumab.
“Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate”, said Gardiner F.H. Smith, Chief Executive Officer of TenX Biopharma. “We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.